What Is Kanna? A Plain-English Guide for 2026
Kanna is a succulent plant native to South Africa that has been used by indigenous San and Khoikhoi peoples for centuries, primarily as a mood-supporting substance and social lubricant. In the last several years, kanna has attracted attention in wellness circles as a natural product with potential anxiolytic and mood-lifting properties. This guide explains what kanna is, what the available science says, and how it fits into the broader landscape of mental wellness options in 2026.
What Kanna Is
Kanna is the common name for Sceletium tortuosum, a low-growing succulent found primarily in the Western and Eastern Cape provinces of South Africa. The plant has a long documented history of traditional use: it was chewed, smoked, or used as snuff by indigenous peoples for its mood-altering effects, particularly during ceremonies, long journeys, or times of social gathering.
The plant contains alkaloids — primarily mesembrine, mesembrenone, and related compounds — that appear to act primarily as serotonin reuptake inhibitors (SRIs) and PDE4 inhibitors. This means kanna’s mechanism of action has some overlap with pharmaceutical antidepressants, though the compounds involved, the potency, and the pharmacological profile are quite different from prescription SSRIs.
Kanna is sold today primarily as a dietary supplement in the United States, in various forms including capsules, tinctures, and raw fermented plant material. Fermentation is the traditional preparation method and is thought to enhance bioavailability of the active alkaloids.
What the Research Shows
Kanna is not a well-studied compound by pharmaceutical standards. There are no large-scale randomized controlled trials in humans comparable to what would be required for FDA drug approval. What exists is a body of in vitro research, animal studies, small human trials, and a longer tradition of reported use.
A double-blind, randomized, placebo-controlled trial published in the Journal of Ethnopharmacology found that a standardized kanna extract (Zembrin) showed cognitive and emotional benefits in healthy adults, including effects on stress reactivity and working memory, at doses of 25mg per day. This is one of the more rigorous human studies available, though the sample size was small.
A proprietary standardized extract, Zembrin, has been the subject of most of the published clinical research on kanna. Products using unstandardized raw plant material may have significantly different alkaloid content and have been studied less rigorously.
It would be inaccurate to describe kanna as a proven treatment for depression, anxiety, or any other diagnosed condition. It is sold and regulated as a dietary supplement in the US, not as a medicine. Descriptions of its effects should be understood in that context.
How Kanna Differs from Pharmaceutical Options
People exploring kanna often ask how it compares to prescription antidepressants or to compounds like ketamine. The honest answer is that they are operating in very different regulatory and evidence categories.
Prescription SSRIs (sertraline, escitalopram, fluoxetine, etc.) have been through extensive clinical trials, FDA review, and decades of post-market safety data. They are prescribed by a licensed clinician, monitored, and adjusted based on individual response. Ketamine’s psychiatric use, while off-label, is conducted in a supervised medical setting.
Kanna is available over the counter as a supplement. No FDA review of efficacy is required for dietary supplements under current law (the Dietary Supplement Health and Education Act, DSHEA). This does not mean kanna is unsafe or ineffective — it means the regulatory bar for its sale is different, and individuals using it are operating with less institutional oversight of quality and dosing than they would have with a prescription medication.
For anyone considering kanna alongside prescription medications — especially SSRIs or other serotonergic drugs — consulting a pharmacist or physician is genuinely important. Combining serotonergic substances without clinical guidance carries theoretical risk of serotonin-related adverse effects.
Kanna in the 2026 Wellness Landscape
Kanna occupies an interesting niche in 2026. As interest in plant-based mental wellness options has grown alongside wider cultural awareness of psychedelic-assisted therapy, kanna has attracted attention as a legal, accessible alternative to more regulated compounds. It is not a psychedelic in the conventional sense — typical doses do not produce hallucinations or dramatic alterations of consciousness — but it does produce noticeable mood and anxiety effects that many users find meaningful.
The lack of a strong pharmaceutical industry behind kanna means product quality varies significantly. If you are interested in trying kanna, looking for products that use standardized extracts with documented alkaloid content, rather than raw plant material with unknown potency, is a reasonable approach.
For more information about how kanna fits into a broader wellness plan, reach out to our team here. We are happy to answer questions and point you toward credible resources.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.
Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.